Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
Condition: Psoriasis Vulgaris
MeSH terms: Psoriasis
Intervention: calcipotriol and betamethasone (LEO 80185 gel); LEO 80185 vehicle; Tacalcitol ointment
Intervention description: Once daily application; Once daily application; Once daily application
Intervention MeSH terms: Betamethasone; 1 alpha,24-dihydroxyvitamin D3; Calcipotriene
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Enrollment: 458.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This study will compare efficacy and safety of once daily treatment of calcipotriol plus
      betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle
      alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks
      followed by an observation period of up to 8 weeks to investigate the occurence and the time
      to relapse and occurence of rebound after discontinuation of the investigational products.
      Only subjects with "controlled disease" will be considered for this observation phase of the
      study. "Controlled disease" is defined as "Clear" or "Almost Clear" severity category based
      on Investigator's global assessment (IGA).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated informed consent to be obtained prior to any trial related procedure,
             including wash-out

          -  Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs
             amenable to treatment with a maximum of 100 g of LEO 80185 gel per week or 10 g per
             day of tacalcitol ointment

          -  Disease severity graded moderate, severe or very severe according to the
             Investigator's global assessment (IGA) of disease severity

          -  A minimum PASI score for extent of 2 in at least one body region (i.e.psoriasis
             affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)

          -  Subjects aged 18 years or above

          -  Either sex

          -  Any ethnic origin

          -  Attending hospital outpatient clinic or the private practice of a dermatologist

        Exclusion Criteria:

          -  Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept,
             infliximab, adalimumab) within 3 months prior to randomisation

          -  Systemic treatment with all other therapies than biologics, with a possible effect on
             psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4
             weeks prior to randomisation

          -  Systemic treatment with Vitamin D preparations above 500 IU per day

          -  PUVA or Grenz ray therapy within 4 weeks prior to randomization

          -  UVB therapy within 2 weeks prior to randomisation

          -  Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior
             to randomisation

          -  Topical treatment for other relevant skin disorders on the face and flexures (e.g.,
             facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV)
             corticosteroids or vitamin D analogues within 2 weeks prior to randomisation

          -  Topical treatment for other relevant skin disorders on the scalp (e.g. scalp
             psoriasis) with very potent (WHO group IV) corticosteroids or vitamin D analogues
             within 2 weeks prior to randomisation

          -  Planned initiation of, or changes to concomitant medication that could affect
             psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium)
             during the study

          -  Current diagnosis of erythrodermic, exfoliative or pustular psoriasis

          -  Subjects with any of the following conditions present on the treatment area: viral
             (e.g., herpes or varicella) lesions, fungal and bacterial skin infections, parasitic
             infections, skin manifestations in relation to syphilis or tuberculosis, rosacea,
             perioral dermatitis, acne vulgaris, atrophic skin, striae atro-phicae, fragility of
             skin veins, ichthyosis, acne rosacea, ulcers and wounds

          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Known or suspected hypersensitivity to component(s) of the Investigational Products

          -  Current participation in any other interventional clinical study

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within the 4-week period prior to randomisation, except for biologics (3 months)

          -  Planned exposure to sun during the study that may affect psoriasis vulgaris

          -  Previously randomised to this study

          -  Subjects known or suspected of not being able to comply with a trial protocol (e.g.
             due to alcoholism, drug dependency or psychotic state)

          -  Females of child-bearing potential wishing to become pregnant during the study, or are
             breast-feeding, or not using an adequate method of contraception during the study

          -  Females of child-bearing potential with positive pregnancy test at Visit 1